Press release
May 20, 2026
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
MetaVia Inc. (MTVA)
CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel (DA-1241), a novel